Chen‐Yuan Lin

1.1k total citations
24 papers, 333 citations indexed

About

Chen‐Yuan Lin is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chen‐Yuan Lin has authored 24 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 12 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chen‐Yuan Lin's work include Esophageal Cancer Research and Treatment (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Treatments and Mutations (5 papers). Chen‐Yuan Lin is often cited by papers focused on Esophageal Cancer Research and Treatment (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Treatments and Mutations (5 papers). Chen‐Yuan Lin collaborates with scholars based in Taiwan, United States and Japan. Chen‐Yuan Lin's co-authors include P. J. Kahrilas, Dustin A. Carlson, Zhiyue Lin, John E. Pandolfino, Ching‐Chan Lin, Wei‐Chao Chang, Ching-Yun Hsieh, Ling‐Chu Chang, Chi‐Chen Fan and Juan‐Cheng Yang and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMJ Open.

In The Last Decade

Chen‐Yuan Lin

22 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chen‐Yuan Lin Taiwan	9	148	121	84	84	63	24	333
Jun Liang Teh Singapore	7	191 1.3×	266 2.2×	55 0.7×	185 2.2×	42 0.7×	18	469
Mónica Enguita‐Germán Spain	10	112 0.8×	106 0.9×	90 1.1×	162 1.9×	53 0.8×	21	358
Lok Lam Ngai Netherlands	9	130 0.9×	116 1.0×	54 0.6×	178 2.1×	49 0.8×	17	370
Eric Beohou France	12	61 0.4×	144 1.2×	68 0.8×	69 0.8×	58 0.9×	18	385
Bok Ai Choo Singapore	12	160 1.1×	98 0.8×	55 0.7×	144 1.7×	33 0.5×	29	364
Taro Yamato Japan	12	278 1.9×	94 0.8×	67 0.8×	84 1.0×	121 1.9×	21	366
F Latteri Italy	8	76 0.5×	63 0.5×	34 0.4×	55 0.7×	26 0.4×	24	301
Michio Takamura Japan	10	99 0.7×	191 1.6×	56 0.7×	88 1.0×	24 0.4×	34	357
Masaaki Matsukawa Japan	8	226 1.5×	104 0.9×	61 0.7×	181 2.2×	62 1.0×	34	372
И. А. Покатаев Russia	7	78 0.5×	141 1.2×	35 0.4×	101 1.2×	22 0.3×	86	246

Countries citing papers authored by Chen‐Yuan Lin

Since Specialization

Citations

This map shows the geographic impact of Chen‐Yuan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen‐Yuan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen‐Yuan Lin more than expected).

Fields of papers citing papers by Chen‐Yuan Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chen‐Yuan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen‐Yuan Lin. The network helps show where Chen‐Yuan Lin may publish in the future.

Co-authorship network of co-authors of Chen‐Yuan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Chen‐Yuan Lin. A scholar is included among the top collaborators of Chen‐Yuan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chen‐Yuan Lin. Chen‐Yuan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Muh‐Hwa, Shang‐Yin Wu, Nai‐Jung Chiang, et al.. (2025). Nanoliposomal Irinotecan in Combination With 5‐Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum‐Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial. Cancer Medicine. 14(20). e71307–e71307.

Lin, Ching‐Chan, Wen-Jyi Lo, Ching-Yun Hsieh, et al.. (2024). Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. Cancers. 16(6). 1082–1082. 2 indexed citations

Yoon, Harry H., Ken Kato, Richard Hubner, et al.. (2024). Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.. Journal of Clinical Oncology. 42(16_suppl). 4032–4032. 1 indexed citations

Shu, Yongqian, Jufeng Wang, Zhendong Chen, et al.. (2024). Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology. 42(3_suppl). 390–390. 3 indexed citations

Lin, Hsiang‐Wen, Chen‐Yuan Lin, Yu‐Chieh Chen, et al.. (2023). Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research. BMJ Open. 13(3). e059288–e059288. 6 indexed citations

Lin, Chia‐Chi, et al.. (2022). Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma. Esophagus. 19(4). 693–701.

Hsu, Chia‐Lang, Yenlin Huang, Chia‐Chi Lin, et al.. (2022). B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma. Frontiers in Oncology. 12. 879398–879398. 7 indexed citations

Lin, Chen‐Yuan, et al.. (2022). Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study. BMC Gastroenterology. 22(1). 381–381. 1 indexed citations

Hsieh, Ching-Yun, Ching‐Chan Lin, Yu-Wen Huang, et al.. (2022). Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling. JCI Insight. 7(23). 35 indexed citations

10.

Hsieh, Ching-Yun, et al.. (2022). Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial. BMC Cancer. 22(1). 169–169. 7 indexed citations

11.

Fang, Hsin‐Yuan, et al.. (2022). Effectiveness evaluation of adjuvant concurrent chemoradiotherapy for patients with positron emission tomography‐staged esophageal squamous cell carcinoma after complete resection: A population‐based cohort study. Thoracic Cancer. 13(13). 1986–1993. 2 indexed citations

12.

Lin, Chen‐Yuan, et al.. (2021). Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites. Oncology. 99(10). 652–658. 1 indexed citations

13.

Shen, Lin, Ken Kato, Sung‐Bae Kim, et al.. (2021). RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4012–4012. 34 indexed citations

14.

Bai, Li‐Yuan, Muh‐Hwa Yang, Nai‐Jung Chiang, et al.. (2021). A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy.. Journal of Clinical Oncology. 39(15_suppl). 6025–6025. 1 indexed citations

15.

Fan, Chi‐Chen, Chen‐Yuan Lin, Ling‐Chu Chang, et al.. (2020). EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis. Redox Biology. 34. 101571–101571. 42 indexed citations

16.

Hsieh, Ching-Yun, et al.. (2020). Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study. BMC Cancer. 20(1). 832–832. 16 indexed citations

17.

Cho, Byoung Chul, Ken Kato, Masanobu Takahashi, et al.. (2019). Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. Annals of Oncology. 30. v873–v874. 12 indexed citations

18.

Chen, Ming, Long‐Yuan Li, Su‐Peng Yeh, et al.. (2017). A targeted next‐generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice. Cancer Medicine. 6(2). 349–360. 43 indexed citations

19.

Lin, Chen‐Yuan, et al.. (2015). Cost‐effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population‐based matched case‐control study. Thoracic Cancer. 7(3). 288–295. 13 indexed citations

20.

Lin, Ting‐Yu, et al.. (2009). Response of extranodal natural killer/âT-cell lymphoma, nasal type, to interferon-Î±, corticosteroid and narrowband ultraviolet B phototherapy. Clinical and Experimental Dermatology. 34(8). e927–e930. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact